The tendency to have severe attacks of localized alngioneurotic edema may be inherited as an autosomal dominant trait (1) (2) (3) (4) (5) (6) (7) . The hereditary form of angioneurotic edema is also distinguishable by a biochemical abnormality in that affected persons lack detectable serum inhibitor of an enzyme derived from the first component of complement (C'1-esterase) (8) . This serum deficiency is detectable before the onset of symptoms, which may appear at any time from 1 year of age to adult life. Although serum inhibitor of C'1-esterase is constantly absent from sera of patients, attacks of edema are episodic and self-limited and affect only circumscribed areas of the body. The present studies were undertaken to define changes in C'1-esterase and the components of complement in serum of patients during attacks of edema and during asymptomatic intervals.
Affected members of a family reported earlier (9) had no inhibitor of C'1-esterase in their serum, whereas sera from unaffected relatives contained normal amounts. Affected persons also developed C'1-esterase activity in their serum, but relatives and other normal individuals did not. When patients were free of swelling, there was evidence that small amounts of C'1 in their serum had been converted to C'1-esterase. During attacks of superficial swelling, laryngeal edema, or abdominal pain, C'1-esterase activity was readily detectable in both serum and plasma. Thus, symptoms of hereditary angioneurotic edema were associated with enhanced generation of C'1-esterase. Ratnoff and Lepow have demonstrated that C'1-esterase can increase vascular permeability in the skin of the guinea pig and that purified serum inhibitor of C'1-esterase can impair this response (10) . C'1-esterase may also serve to increase vascular permeability in hereditary angioneurotic edema.
Methods
Nomenclature. Complement activity resides in a group of proteins in fresh serum. Although required for immune hemolysis and immune cellular injury in vitro, its role in human physiology is unclear. Four major components of complement are designated by number, indicating chronological order of their discovery: C'1, C'2, C'3, and C'4 (11) . A part of C'1 exists as a proenzyme which, under appropriate conditions, is converted to an active enzyme called C'1-esterase (12) (13) (14) (15) (16) (17) (18) .
Recent studies of Lepow and associates have shown that C'1 may be chromatographically resolved into three subcomponents, referred to as C'lq, C'lr, and C'ls (19) . C'lq is an 11 S globulin, probably identical to the protein that Mfiller-Eberhard and Kunkel called C'O (20) and Taranta, Weiss, and Franklin (21) described as participating in immune hemolysis. C'1r was not identifiable with previously described components of complement and was proposed as a new component (19) . C'1s was chromatographically and antigenically related to C'1-esterase (17) (18) (19) 22 C'l-esterase used in assays to measure the inhibitory properties of serum or plasma samples was prepared from a euglobulin fraction of human serum as described by Lepow, Ratnoff, Rosen, and Pillemer (12) .
Hydrolysis of N-acetyl-L-tyrosine ethyl ester by C'l-esterase was measured with a microformol titration using 0.05 N sodium hydroxide to quantify acid liberated during incubations. One unit of C'l-esterase is that amount which hydrolyzes 0.5 ,mole of N-acetyl-L-tyrosine ethyl ester in a standard 15-minute assay at 370 C (23) . To measure C'l-esterase-like activity in an esterolytic assay, serum or plasma was substituted for C ' The inhibitory property of human serum that is directed against C'l-esterase will be referred to as serum inhibitor of C'l-esterase, even though the inhibitor was not fractionated from serum before assay. Highly purified human serum inhibitor of C'l-esterase was prepared as described by Pensky, Levy, and Lepow (24, 25) . One unit of inhibitor is the amount which inhibits the action of 10 U of C'l-esterase (23) .
The components of complement in serum were titrated by published methods using a hemolytic assay (26) (27) (28) (29) . Serum reagents to measure C'1, C'2, C'3, and C'4 are known as RI, R2, R3, and R4, respectively. These reagents were markedly deficient in the component in question and fulfilled requirements published earlier (26) (27) (28) (29) . In reading complement titrations, a 50%o hemolytic end point was estimated, or hemolysis was measured directly by comparing optical densities of hemolysates at a wave length of 541 m/u in a Beckman DU spectrophotometer. To measure C'3 with sensitized erythrocytes that already contained C'1, C'4, and C'2 activities, the procedure described by Leon was followed (30) .
Sodium phosphate buffer at an ionic strength of 0.15 and pH of 7.4 was used in assays to determine hydrolysis of N-acetyl-L-tyrosine ethyl ester; triethanolaminebuffered saline (TBS) at pH 7.4, ionic strength 0.15, containing 1.5 X 10-' M calcium and 5 X 10-' M magnesium ions, was employed as diluent in hemolytic assays to measure complement or components thereof. The preparation of this buffer has been described (31) .
Subcomponents of C'l were differentiated by means of centrifugation in a preparatory ultracentrifuge, Spinco model L, using a linear density gradient of sucrose varied in concentration from 10%, to 40%. The technique for this separation was modified by Naff, Pensky, and Lepow (32) from the procedure described by Martin and Ames (33) . Subcomponents of Cl were measured in a hemolytic assay designed to measure one in the presence of adequate quantities of the other two, as detailed by Naff and associates (32) .
To measure the effect of C'l-esterase upon C'4, normal pooled human serum that had been heated to 560 C for 30 minutes was used as a source of C'4 free of C'1 and C'2 (34) . Sera from persons with hereditary angioneurotic edema, or fractions thereof, were incubated with this C'4 at 00 C for 30 minutes, and the residual C'4 was titrated in a hemolytic assay using serial dilutions of the incubation mixture and R4. This method of measuring C'l-esterase is much more sensitive than the esterolytic assay and about 100 times as sensitive as titration of residual C'2, which is less readily inactivated by C'l-esterase (34) . The accuracy of the titration is limited by use of double dilutions, rendering a one-tube difference of questionable significance. Immunoelectrophoresis of fresh human serum and "complement fixed" human serum was performed by the method of Grabar and Williams (35) . To prepare complement fixed serum, precipitates of human gamma globulin complexed with rabbit antihuman gamma globulin were washed with cold saline and then incubated with fresh human serum at 370 C for 1 hour. The mixture was then centrifuged at 00 C, and the precipitated aggregates were removed from the complement fixed serum. -After electrophoresis, bands of precipitation were developed with two different rabbit antisera. Rabbit antiserum against human C'4 (,8Ps) was prepared by Dr.
H. J. Miiller-Eberhard (36) . Rabbit antiserum to both human C'4 (,8B) and to a portion of C'3 (,ic) (37) was prepared by Dr. Franz Peetoom by injecting rabbits with ovalbumin-rabbit antiovalbumin precipitates that had been incubated in fresh human serum and then washed with cold saline (38) . Partially purified C'l-esterase in assay systems designed to detect the component in question. Normal serum contained no C'1-esterase activity, and titers of C'4 and C'2 were in the ranges shown in Table II . Serum obtained from patients during attacks of abdominal pain, swelling of the hands, and glottic edema contained readily measurable C'1-esterase activity and no detectable C'4 or C'2 (Table II) . When hand swelling had subsided, C'1 esterase was no longer detectable in a patient's serum, but C'4 and C'2 were decreased. Other patients also had diminished amounts of C'4 and C'2 in their serum when free of swelling (Table II) , as if small amounts of C'1-esterase were generated in the blood even between attacks.
Results
When immune hemolysis occurs, C'3 acts after the participation of the other three major components of complement. However, serum from persons with hereditary angioneurotic edema had normal amounts of C'3 (Table II) . Some other serum samples containing C' 1-esterase activity, but lacking hemolytic C'1, did not provide a satisfactory assay medium for detection of hemolytic C'3 with a conventional R3 and a one-step assay procedure. Sensitized sheep erythrocytes were incubated with C'1, C'4, and C'2 before measurement of C'3 in a two-step assay as described by Leon (30) . When this procedure was used, similar amounts of C'3 were measurable in serum obtained from patients during and between attacks.
Immunoelectrophoretic studies of patient's sera provided confirmatory evidence that C'4 was altered while C'3 was unaffected (Figure 3 Samples of EDTA plasma obtained from a patient during an attack of hereditary angioneurotic edema were incubated with buffer and N-acetyl-L-tyrosine ethyl ester (ALTEE). After 15 and 60 minutes of incubation at 370 C, 1.0-ml samples of the mixtures were pipetted into 1.0 ml of neutral formaldehyde. Titratable acid in these mixtures was measured with a microformol titration using 0.05 N NaOH. Acid titrated at 15 and 60 minutes was compared to that in the original mixture before incubation.
Each curve represents C'1-esterase activity, as determined in this assay, which was found in plasma at the time denoted during and after an attack of severe abdominal pain. When pain subsided and the patient was able to be up and about, the attack was considered over. parent in Figure 3, (32) . These subcomponents have sedimentation constants of 11 S, 7 S, and 4 S and are respectively designated C'lq, C'lr, and C'ls (19) . When serum is ultracentrifuged in a density gradient, intact C'1 and subcomponents thereof are all recovered from the bottom of the gradient, indicating that C'1 exists as a macromolecule in serum (32) . It was of interest to determine whether the esterase activity in serum of a person with hereditary angioneurotic edema is associated with the macromolecular fraction in which C'1 is located in normal serum.
EDTA plasma and serum of a patient having an episode of swelling were ultracentrifuged in a sucrose density gradient. To identify C'1-esterase in fractions of the gradient mixture after centrifugation, the ability of these fractions to inactivate C'4 was tested. The serum and plasma used in this part of the experiment contained no measurable C'1, C'4, or C'2 and had 24 U of C'1-esterase per ml.
In serum of patients, both C'ls and C'1-esterase were recovered from fractions at the bottom of the density gradient, which contained proteins of high molecular weight; in EDTA plasma of patients, both were found with lower molecular weight materials (4 S). possible that the C1-esterase activity in the blood of these individuals had all been generated after phlebotomy in vitro, and that free esterase activity did not actually exist in vivo. To establish the in vivo presence of C'1-esterase activity, blood was drawn from a normal individual and from a patient not having edema into a syringe containing enough purified inhibitor of C'1-esterase to provide a normal concentration of the material in the volume of blood obtained. The amount of C'4 and-of inhibitor of C'1-esterase was then measured in each serum sample. The amount of C'4 in the serum from a patient was already decreased, whereas that from the normal was not (Table III) . This finding is consistent with the view that C'1-esterase acts upon C'4 in vivo in blood of persons with hereditary angioneurotic edema, rather than being an artifact resulting from in vitro generation of C'1-esterase. The quantity of inhibitor was increased as predicted in the normal serum sample (Table III) and also increased in serum of the patients.
Discussion
Seven of twelve members of a kindred lacked measurable serum inhibitor of C'1-esterase (Figure 1) . The presence of this abnormality in a person subject to characteristic attacks of swelling and pain favors the diagnosis of hereditary angioneurotic edema (8) . Sera from over 500 other persons in health and disease have all contained inhibitor (8, 40) . The incidence of this serum defect and of persons known to have attacks of edema in this kindred is consistent with the expression of an autosomal dominant trait. In this family, two children in generation VI (Figure 1 ) lacked inhibitor but have not yet had attacks of edema. In a family reported earlier, one of the children who lacked inhibitor has since begun to have episodes of localized swellings of the skin at 4 years of age. It is likely that the same fate awaits the children presently reported whose sera contain no inhibitor but who do not yet have symptoms. Serum and plasma from members of family S (Figure 1 ) who lacked serum inhibitor of C'1-esterase hydrolyzed N-acetyl-L-tyrosine ethyl ester, which is digested by C'1-esterase but not by thrombin or plasmin, other hydrolytic enzymes sometimes found in serum and plasma. Purified human serum inhibitor of C'1-esterase blocked this esterolytic property in serum (Table I ). In addition, the fourth (C'4) and the second (C'2) components of complement, both of which are inactivated in appropriate solutions by C'1-esterase, were decreased or absent in sera having this enzymatic activity. Doubtless, the esterase activity in serum and plasma obtained between attacks was largely generated in vitro during assay (Figure 2) , for both C'4 and C'2 were detectable in such serum samples. Therefore, in the absence of the serum inhibitor there is a tendency to enhanced generation of C'1-esterase in the blood of persons with hereditary angioneurotic edema. Blood drawn from a patient free of swelling into purified serum inhibitor of C'1-esterase already had decreased quantities of C'4, indicating that small amounts of C'1-esterase had acted in vivo.
The increased amounts of C'1-esterase activity in serum and plasma of patients having attacks of swelling or pain suggested that C'1-esterase might have caused increased vascular permeability in susceptible areas of the body of a person with hereditary angioneurotic edema. Purified C'1-esterase can effectively increase vascular permeability in the skin of the guinea pig, and purified inhibitor can block this response in a predictable fashion (10). Landerman, WVebster, Becker, and Ratcliffe also reported that autologous intracutaneous injections of diluted serum from a patient with hereditary angioneurotic edema induced marked wheal formation, in contrast to similar injections of diluted normal serum (41) . It is not clear how C'1-esterase may increase vascular permeability. A subsequent biochemical event in the series initiated by activation of C'1 may be responsible. Since C'3 is apparently not altered in hereditary angioneurotic edema, the interactions between C'1-esterase and C'4 and C'2 may generate a factor that increases vascular permeability.
Evidently only a small portion of C'1 is converted to C'1-esterase in persons with hereditary angioneurotic edema who are not having attacks. There may be normal or slightly decreased quantities of hemolytic C'1 in their serum (Table II) . Even so, amounts of C'4 and C'2 measured in similar assays were significantly reduced, reflecting the susceptibility of these components to inactivation by C'1-esterase. One unit of C'1-esterase can inactivate over 12,000 U of C'4 and 120 U of C'2, according to it vitro observations of Haines and Lepow (34) . A possibility to be considered was that C'1-esterase in serum of a patient could have resided in a low molecular weight fraction, in contrast to the localization of C'ls (proesterase) in high molecular weight fractions of normal serum. In patients' serum, however, active C'1-esterase was in fractions of higher molecular weight after ultracentrifugation in a sucrose density gradient. In addition, subcomponents of C'1 (C'lq, C'lr, and C'ls) were in fractions of similar molecular weights in plasma from a patient and from a normal person, and in serum from a patient and a normal person. These experiments did not differentiate the subcomponents of C'1 in hereditary angioneurotic edema from normal; enzymatically active C'1 (C'1-esterase) was located in fractions known to contain C'ls activity normally. Evidently C'1 activation did not require that the molecule be dissociated.
Miiller-Eberhard, Nilsson, and Aronsson described a 31c globulin in fresh serum that can be substituted for guinea pig C'3 activity in a reagent markedly deficient in this component (39, 42) .
The human hlc represents a portion of human C'3 (37) . During complement fixation, the electrophoretic mobility of antigenic 81c globulin in fresh serum was altered to that of a lhA globulin (42) . This alteration was evidently related to the participation of C'3 in the interactions of complement with antigen-antibody aggregates. Additional studies of Miuller-Eberhard and Biro have identified a 81E globulin of human serum with C'4 (36) .
Titers of C'4 and C'2 were always decreased in serum from patients with hereditary angioneurotic edema, and immunoelectrophoretic patterns demonstrated altered 81E precipitin bands in hereditary angioneurotic edema and complement fixed serum, indicating changes in C'4 in both situations ( Figure 3) . Titers of C'3 in patients' sera did not vary from those in normal sera, and the shift of antigenic lic globulin to a 813A position observed in complement fixed serum was absent in normal and hereditary angioneurotic edema sera (Figure 3) . Therefore, the changes in C'3 occurring during complement fixation were not present in hereditary angioneurotic edema.
C'1-esterase may be one of several factors in human serum able to increase vascular permeability. Landerman and associates (41) reported that a patient with hereditary angioneurotic edema had decreased amounts of serum inhibitor of kallikrein, a serum enzyme capable of increasing vascular permeability by initiating the release of plasma kinins (43) (44) (45) (46) (47) (48) . They suggested that kallikrein might initiate edema formation in hereditary angioneurotic edema. Later, Kagan and Becker (49) reported that purified serum inhibitor of C'1-esterase impaired the action of a preparation of human plasma kallikrein and of PF/DIL, another permeability factor of serum (50) . These reports suggested a relationship between these permeability factors and the complement system. However, C'1-esterase must not be identical with kallikrein or PF/DIL. C'1-esterase hydrolyzed .V-acetyl-L-tyrosine ethyl ester (12) , whereas preparations of plasma kallikrein did not (51) .
Moreover, C'1-esterase was not inhibited by soy bean trypsin inhibitor (15) , but the plasma kallikrein and PF/DIL were (50, 51) . Ultracentrifuge experiments tend to identify enzymatic activity in serum of patients with hereditary angioneurotic edema with C'ls, the proesterase found in normal serum.
The events leading to enhanced generation of C' 1-esterase in blood of these patients are still undefined. Situations presenting a patient with emotional or physical trauma may precede an attack (8) , and psychiatric studies of some of the members of the kindred presently described have been published (9) . Although activation of C'1 in zitro can be readily accomplished upon contact with antigen-antibody aggregates, evidence that such an immune mechanism plays a role in inducing attacks of hereditary angioneurotic edema is unconvincing (7, 8) . Possibly, the fibrinolytic protease, plasmin, becomes active during stress and in turn activates C'1-esterase, as suggested earlier (8) . Plasmin can activate C'l proesterase under suitable in vitro conditions (15) ; anxiety, exercise, and injections of adrenaline can enhance the fibrinolytic activity of the blood in vivo, presumably by inducing the formation of plasmin (52, 53) .
One of the most entrancing features of this disease remaining unexplained is the mechanism causing cessation of symptoms. Edema may subside rather suddenly, and the patient is well aware that his attack of swelling or pain is abruptly terminating. Attacks usually last 2 or 3 days and maintain their episodic nature. It is possible that tissue factors determine the end of swelling. Alternatively, mechanisms that enhance generation of C'1-esterase may cease to be effective, or a substrate required for continuation of enzymatic events may become exhausted.
Summary
Affected members of a kindred with hereditary angioneurotic edema lacked detectable serum inhibitor of C'1-esterase, which was present in a large group of other persons in health and disease. C'1-esterase activity found in their serum and plasma was markedly enhanced during attacks of angioneurotic edema but was not detectable in normal serum or plasma. Enhanced activation of C'1-esterase was associated with increased vascular permeability characterizing attacks. In intervals between attacks of edema, hemolytic C'2 and C'4 were diminished; during attacks these activities were absent. C'3 levels remained normal in serum during and between attacks. Immunoelectrophoretic examination of sera also demonstrated that C'4 was altered while C'3 was unchanged.
Blood drawn from patients into highly purified serum inhibitor of C'1-esterase had diminished amounts of C'4. Therefore, C'1-esterase had apparently acted in vivo to reduce C'4, and this reduction was not an in vitro artifact.
The macromolecular nature of C' 1 in normal serum (32) 
